#LCSM Chat 06/02: Open Mic Nite–What’s on your mind?
On Thursday June 2, 2016, at 8 PM Eastern (5 PM Pacific), #LCSM Chat will hold an Open Mic Nite to talk about whatever lung cancer topics are foremost on our minds. This would be a particularly good chat for those who are just starting with Twitter or tweet chats (please check out our tweetchat primer).
Moderator Deana Hendrickson will post the following questions to stimulate discussion:
- T1: What do you wish you had known when you were first starting on your journey with lung cancer? What would you have done differently?
- T2: What are your thoughts about dealing with treatment, side effects, survivorship?
- T3: What are your thoughts about patient-doctor communication?
- T4: What is most important for your patient/caregiver/doctor to know about you?
We know many in the #LCSM community will be traveling or already at the ASCO (American Society for Clinical Oncology) Annual Conference in Chicago June 2-6; we look forward to your live tweets about the latest research in lung cancer!
Hope to see you Thursday June 2 for #LCSM Chat on Twitter at 8 PM Eastern time.
#LCSM Chat 5/26: Top 10 Key Abstracts on Lung Cancer (and Mesothelioma) at ASCO 2016: An #LCSM Preview
By Jack West, MD
For the upcoming #LCSM chat on Thursday, 5/26 at 8 PM Eastern (5 PM Pacific) we’re going to do a preview of what are likely to be the most notable and clinically relevant presentations in lung cancer, and one in mesothelioma, at the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago in early June. This meeting brings together over 30,000 cancer specialists every year to review thousands of presentations. Nobody can see it all, and one important aspect of not being overwhelmed is knowing what should be the focus of your attention.
The abstracts for these presentations have just been released, and on Thursday, we’re going to briefly review the subject and key findings for 10 in lung cancer that have the most promise for the thoracic oncology community. This won’t be the usual open question and answer format, but instead we’ll spend about 5 minutes covering each of these and welcoming your questions and comments and have some discussion on the potential implications of these presentations.
Here they are, in the order we’ll be covering them:
- The multikinase inhibitor vandetanib demonstrates marked activity against the 2% of NSCLC cancers with RET fusions (Abstract #9012)
- The PD-L1 inhibitor avelumab has limited activity in malignant pleural mesothelioma (Abstract #8503)
- Weekly Taxol/Avastin vs. Taxotere every 3 weeks in previously treated advanced NSCLC (Abstract #9005)
- Daily vs. twice daily chest radiation with concurrent chemotherapy for limited disease SCLC (Abstract #8504)
- Tagrisso (osimertinib) in treatment of leptomeningeal carcinomatosis in paitents with EGFR mutation-positive advanced NSCLC (Abstract #9002)
- Comparison of tissue, plasma, and urine testing for EGFR T790M trial with rociletinib (Abstract #9001)
- Local “consolidation” therapy of radiation or surgery after first line systemic therapy in advanced NSCLC (Abstract #9004)
- Addition of low molecular weight heparin to adjuvant chemotherapy after surgery for early stage NSCLC (Abstract 8506)
- Rova-T, an antibody-drug conjugate, in treatment of recurrent or refractory SCLC (Abstract #LBA8505, a “late breaking abstract” not yet available)
- Alecensa vs. Xalkori as initial ALK inhibitor therapy in Japanese patients with ALK-positive NSCLC: The J-ALEX trial (Abstract #9008)
You can review the highlights in advance through this link to my slideshare presentation of top 10 lung cancer abstracts for ASCO 2016.
I hope you’ll join us for the ASCO preview on Thursday May 26 at 8pm Eastern (5pm Pacific)! If you’re new to tweetchats, please read this primer on how to participate in #LCSM Chats.
#LCSM Chat 5/5: Know Before You Go—Conference Prep 101
image by Microsoft Office
Lung cancer patients and advocates are increasingly joining healthcare, pharma, government agency and biotech industry representatives at cancer-related medical conferences such as the American Association for Cancer Research (AACR) Annual Meeting in April and the American Society for Clinical Oncology Annual Meeting in June.
Planning ahead for these meetings is essential for getting the most out of your time. The events, which can last several days, often have many sessions happening at the same time in different rooms. In addition to scheduling considerations, the terminology, graphics, and scientific concepts discussed in the sessions can be overwhelming even for seasoned attendees.
Because no one can possibly attend every conference, attendees share the conference experience by posting tweets while at the conference (called “live tweeting”) about significant happenings and new findings. Often, these conferences have specific hashtags–for instance, those attending the ASCO Annual Meeting this year will include #ASCO16 in their tweets. However, live tweeting from sessions presents some challenges, like condensing new concepts into less than 140 characters, and continuing to follow slides while composing tweets.
In our Thursday May 5 #LCSM Chat at 8 PM Eastern Daylight Time (5 PM Pacific), we will share ideas how attendees might prepare in advance to get the most from a medical conference and share their conference experience with others in real time on Twitter. Janet Freeman-Daily will moderate our discussion using the following questions:
- T1: What tips do you have for getting the most out of a medical conference? How do you prepare?
- T2: What concepts would be most helpful for patients/advocates to know before attending cancer conferences? Where can they learn these?
- T3: What tips do you have for live tweeting a medical conference? What kind of live tweets do you value most?
We hope you’ll join #LCSM Chat on Thursday May 5 at 8 PM EDT. If you’re new to tweetchats, please read this primer on how to participate in #LCSM Chats.
#LCSM 
You must be logged in to post a comment.